Establishment Labs (NASDAQ:ESTA – Get Free Report) and DocGo (NASDAQ:DCGO – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Institutional and Insider Ownership
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Establishment Labs and DocGo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -19.05% | -218.77% | -12.31% |
| DocGo | -62.23% | -44.09% | -29.14% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $211.08 million | 12.91 | -$51.06 million | ($1.49) | -62.13 |
| DocGo | $322.20 million | 0.20 | -$182.40 million | ($1.91) | -0.34 |
Establishment Labs has higher earnings, but lower revenue than DocGo. Establishment Labs is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Establishment Labs has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Establishment Labs and DocGo, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 1 | 7 | 0 | 2.67 |
| DocGo | 1 | 2 | 3 | 0 | 2.33 |
Establishment Labs currently has a consensus price target of $90.43, suggesting a potential downside of 2.32%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 264.71%. Given DocGo’s higher probable upside, analysts plainly believe DocGo is more favorable than Establishment Labs.
Summary
Establishment Labs beats DocGo on 10 of the 14 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About DocGo
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
